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Abstract
Background: Many cancer cells produce interleukin-6 (IL-6), a cytokine that plays a role in growth
stimulation, metastasis, and angiogenesis of secondary tumours in a variety of malignancies, including
colorectal cancer. Effectiveness of IL-6 in this respect may depend on the quantity of basal and inducible
IL-6 expressed as the tumour progresses through stages of malignancy. We therefore have evaluated the
effect of IL-6 modulators, i.e. IL-1β, prostaglandin E2, 17β-estradiol, and 1,25-dihydroxyvitamin D3, on
expression and synthesis of the cytokine at different stages of tumour progression.
Methods: We utilized cultures of the human colon carcinoma cell clones Caco-2/AQ, COGA-1A and
COGA-13, all of which expressed differentiation and proliferation markers typical of distinct stages of
tumour progression. IL-6 mRNA and protein levels were assayed by RT-PCR and ELISA, respectively.
DNA sequencing was utilized to detect polymorphisms in the IL-6 gene promoter.
Results: IL-6 mRNA and protein concentrations were low in well and moderately differentiated Caco-2/
AQ and COGA-1A cells, but were high in poorly differentiated COGA-13 cells. Addition of IL-1β (5 ng/
ml) to a COGA-13 culture raised IL-6 production approximately thousandfold via a prostaglandin-
independent mechanism. Addition of 17β-estradiol (10-7 M) reduced basal IL-6 production by one-third,
but IL-1β-inducible IL-6 was unaffected. Search for polymorphisms in the IL-6 promoter revealed the
presence of a single haplotype, i.e., -597A/-572G/-174C, in COGA-13 cells, which is associated with a high
degree of transcriptional activity of the IL-6 gene. IL-6 blocked differentiation only in Caco-2/AQ cells and
stimulated mitosis through up-regulation of c-myc  proto-oncogene expression. These effects were
inhibited by 10-8 M 1,25-dihydroxyvitamin D3.
Conclusion: In human colon carcinoma cells derived from well and moderately differentiated tumours,
IL-6 expression is low and only marginally affected, if at all, by PGE2, 1,25-dihydroxyvitamin D3, and 17β-
estradiol. However, IL-6 is highly abundant in undifferentiated tumour cells and is effectively stimulated by
IL-1β. In case of overexpression of an IL-6 gene variant with extreme sensitivity to IL-1β, massive release
of the cytokine from undifferentiated tumour cells may accelerate progression towards malignancy by
paracrine action on more differentiated tumour cells with a still functioning proliferative IL-6 signalling
pathway.
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Background
Interleukin-6 (IL-6) is an immunomodulatory cytokine
[1], which also plays a role in growth stimulation, metas-
tasis, and angiogenesis in secondary tumours in a variety
of malignancies [2], including colorectal cancer [3-7]. IL-
6 can be released from tumour infiltrating leukocytes [8],
but is produced to a large extent by tumour cells them-
selves: In human colon cancer, IL-6 expression parallels
tumour progression, reaching a maximum in high grade
cancerous lesions [5]. Only still differentiated colon carci-
noma cells are responsive to the growth stimulatory
action of IL-6 [5]. We therefore reasoned that IL-6, when
released from rather undifferentiated colon carcinoma
cells, may aid tumour progression by a paracrine-induced
proliferation of still differentiated neoplastic cells [5]. In
addition, IL-6 increases invasiveness of colon cancer cells
[6] and likely promotes secondary tumour formation
through its angiogenic potency. How effective IL-6 is in
promoting progression and metastatic spread of colon
cancer, depends not only on the extent of basal but,
importantly, on the extent of inducible IL-6 expression at
certain stages of tumour development.
IL-6 expression is highly inducible in different cell types
by a variety of cytokines, particularly IL-1β [9-12], by
prostaglandins [12,13], steroid hormones, such as estro-
gen [14] or 1,25-dihydroxyvitamin D3 [13,15]. Although
these substances influence colon carcinoma cell growth,
their ability to regulate IL-6 activity in this cell type has
not yet been evaluated in detail. The present study was ini-
tiated to assess the potential of the aforementioned agents
in modulating IL-6  transcriptional activity and protein
synthesis at different stages of human colon cancer pro-
gression.
Methods
Human colon carcinoma primary cell clones and cell lines
From the Caco-2 cell line (ATCC HTB-37), which was
originally derived from a well differentiated human colon
adenocarcinoma, a number of homogenous and stable
Caco-2 clones were established in several laboratories. For
the present study, we used the clone Caco-2/AQ, which
was derived from the Caco-2/15 clonal line [16] as
described before [17]. Caco-2/AQ cells undergo spontane-
ous differentiation on transition into the post-confluent
state, as indicated by a steep rise in differentiation mark-
ers, i.e. alkaline phosphatase activity (cf. Table 1).
Primary colon adenocarcinoma cell clones COGA-1 and
COGA-13 were isolated by Drs. Ernst Wagner and Alexan-
dra Sinski at Boehringer Ingelheim Austria, Vienna, as
described in detail elsewhere [18]. From the COGA-1
clonal cell line, which was derived from a Dukes' stage B,
pT3, moderately differentiated (i.e. G2) carcinoma, a
morphologically homogenous sub-clone, designated
COGA-1A, was established and characterised with respect
to growth behaviour and degree of differentiation, i.e.,
alkaline phosphatase activity (Table 1; cf. [5]).
COGA-13 cells, which were derived from a stage pT2 car-
cinoma graded G3, exhibit only weak alkaline phos-
phatase activity (Table 1). In addition to the epithelial cell
marker cytokeratin 8 (CK8), COGA-13 cells express also a
high level of vimentin [19]; this indicates that they had
undergone epithelial-mesenchymal transition.
Cell culture
Human colon cancer cells were routinely cultured in
vented tissue culture flasks (Asahi Techno Glass Corpora-
tion, Iwaki Scitech division, Tokyo, Japan) at 37°C in a
humidified atmosphere of 95% air and 5% CO2. Culture
medium was DMEM supplemented with 4.0 mM
glutamine, 10% (v/v) fetal calf serum (FCS) (heat-inacti-
vated at 56°C for 30 min), 20 mM HEPES, 50 U/ml pen-
icillin and 50 μg/ml streptomycin. Cultures were re-fed
every 48 h and subcultured serially when approximately
80% confluent. Cells between passages 6 and 24 were cul-
tured for indicated time periods in the absence or pres-
ence of one of the following treatments: 5 ng/ml IL-1β
(ImmunoTools, Friesoythe, Germany); 10-6 M indometh-
acin, 10-7 M PGE2, 10-7 M 17β-estradiol, 10-6 M NS398 (all
from Sigma), and 10-8 M 1,25-(OH)2D3 (a generous gift
from Hoffmann-La Roche, Basle, Switzerland).
The effect of 0.1 – 100 ng/ml recombinant human (rh) IL-
6 (Strathmann Biotec AG, Hamburg, Germany) on cellu-
lar proliferation was determined by measurement of
Table 1: Characteristics of human colon carcinoma cell lines
Caco-2/AQ COGA-1A COGA-13
Log phase doubling time (h) 24 15 48
Alkaline phosphatase (mU/μg 
cellular protein)
60.2 ± 9.1 2.9 ± 0.1 0.7 ± 0.2
Protein
CK8 +++ +++ +
Vimentin + + +++
Cyclin D1 + ++ +++
p27 +++ ++ +/-
mRNA expression
CYP24
basal +/- ++ +++
after 1,25-(OH)2D3
a +++ +++ +++
CYP27B1 +++ +/- +/-
VDR +++ +++ ++
ER-α +/- +/- +/-
ER-β +++
For details see [5,19,24]. Protein and mRNA expression in confluent 
cells were classified by visual inspection of Western blots or RT-PCR 
gels as: nil, -; low, +; medium, ++; high, +++.
a after treatment with 1,25-(OH)2D3 (cf. [19])BMC Cancer 2008, 8:13 http://www.biomedcentral.com/1471-2407/8/13
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[3H]thymidine incorporation into cellular DNA. Degree
of cellular differentiation was evaluated in confluent cells
from activity of the marker enzyme alkaline phosphatase
as described in detail previously [20]: Enzymatic activity
was assayed using p-nitrophenol as substrate, and normal-
ised to cellular protein content, which was determined
using the BCA Protein Assay Kit (Pierce, Rockford, IL).
Reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA was extracted by using Trizol (GibcoBRL). 2 μg
RNA were reverse transcribed with random hexamer prim-
ers using a cDNA synthesis kit (SuperScript™ II, Invitro-
gen). First-strand cDNA was amplified with primer pairs
for IL-6, and for the reference gene and epithelial cell
marker CK8, respectively (MWG-Biotech AG, Ebersberg,
Germany). To amplify a 349 base pair segment of IL-6
cDNA, primer pairs used were 5'-TTC-AAT-GAG-GAG-
ACT-TGC-CTG-3' (sense) and 5'-ACA-ACA-ACA-ATC-
TGA-GGT-GCC-3' (antisense) [21]. The primer pairs for c-
myc were 5'-GGC-TTT-ATC-TAA-CTC-GCT-GT-3' (sense)
and 5'-GAG-GTC-ATA-GTT-CCT-GTT-GG-3' (antisense)
to amplify a 461 base pair segment [22]. Primer pairs for
a 520 base pair segment of the CK8 gene were 5'-TGG-
GCA-GCA-GCA-TTA-ACT-TTC-3' (sense) and 5'-AGG-
CGA-GAC-TCC-AGC-TCT-AC-3' (antisense) [23]. With
the aid of the GeneAmp PCR System 9600 (Perkin-Elmer,
Norwalk, CT), the thermocycling conditions began with
94°C for 2 min followed by 34 cycles (IL-6) and 30 cycles
(CK8), respectively, of: 94°C 15 sec, 62°C 30 sec, 72°C
45 sec, or followed by 30 cycles (c-myc) of 94°C 30 sec,
57°C 60 sec, 72°C 60 sec. Each run was concluded by 10
min at 72°C. PCR conditions and primer pairs for cDNA
amplification of CYP27B1, CYP24, and VDR were previ-
ously provided elsewhere [19], as well as for cDNA ampli-
fication of ER-α and ER-β [24]. A 1:1 mixture of PCR
products and CK8 amplificates from the same sample was
separated on 2% agarose gels and then visualised with
ethidium bromide. No bands were visible in negative con-
trols that were performed for all primer pairs.
Determination of protein
IL-6 concentrations in cell culture supernatants were
determined by enzyme-linked immunosorbent assay
(ELISA) (eBioscience, San Diego, CA) according to the
protocol of the manufacturer. Since preliminary data had
indicated that some clones might produce IL-6 in
amounts close to the detection limit of the assay (2 pg/ml
IL-6), we added a constant background of 10 pg/ml IL-6
to all samples to improve intra-assay accuracy. Immunob-
lotting for CK8, vimentin, cyclin D1, and p27 has been
described elsewhere [19].
DNA isolation and sequence analysis
Human genomic DNA was extracted from confluent
colorectal cell clones. Cells were trypsinised and washed
twice with PBS before suspension in extraction buffer (50
mM Tris / HCl pH 8, 100 mM EDTA, 100 mM NaCl, 1%
SDS, 0.5 mg/ml proteinase K) and overnight shaking on
an Eppendorf shaker at 55°C. Saturated NaCl (6 M) (a
third of the volume of extraction buffer) was added before
centrifugation at 13000 rpm for 10 min on a Microfuge
Lite Centrifuge (Beckman Coulter, Fullerton, CA). The
supernatant was treated with approximately the same
amount of isopropanol, shaken thoroughly, and centri-
fuged (13000 rpm, 5 min). Thereafter, the pellet was
washed with EtOH (70%, v/v), resuspended in 400 μl TE
buffer (10 mM Tris, pH 8 / 1 mM EDTA), and agitated on
an Eppendorf shaker at 65°C for 15 min. DNA was stored
at -20°C until analysed. DNA amplification was per-
formed with a GeneAmp PCR System 9600 (Perkin-
Elmer, Foster City, CA) as described previously [25]. PCR
products were subsequently purified using the Centri Sep
96 system (Princeton Separations, NJ), and thereafter sub-
jected to sequencing using Big Dye Terminator Cycling
Sequencing kit, version v3.1, and the ABI Prism 310
Genetic Analyzer (Applied Biosystems, Foster City, CA)
according to the manufacturer's recommendation. Prim-
ers for amplification and sequencing were applied as
listed in [9].
Statistical analysis
Statistical analyses were conducted with use of the soft-
ware packages S-PLUS (version 4.5, Lucent Technologies
Inc., Murray Hill, NJ) and SPSS (version 12.0.1, SPSS Inc.,
Chicago, IL). The normal distribution of all data sets was
verified with the aid of the one-sample Kolmogorov-Smir-
nov goodness of fit-test; as a result the unpaired Student's
t-test was used throughout. With a confidence level of
0.95, differences were considered statistically significant
with *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Results
Validation of human colon carcinoma cell clone models
We had availed ourselves of three human colon carci-
noma-derived cell clones, i.e. Caco-2, COGA-1A, and
COGA-13, which we had characterised previously with
respect to their log phase growth behaviour and to expres-
sion of the differentiation marker alkaline phosphatase
[5] (Table 1). For the purpose of the present study, the
proliferative potential was evaluated by determination of
the cell cycle regulators, cyclin D1, which promotes G1/S
transition, and p27, a cdk-inhibitor. We also determined
expression of the epithelial and mesenchymal cell mark-
ers, cytokeratin 8 (CK8) and vimentin, respectively. Fur-
thermore, we checked for expression of the vitamin D
metabolising enzymes, 25-hydroxy-vitamin D-24-hydrox-
ylase (CYP24) and 25-hydroxy-vitamin D-1α-hydroxylase
(CYP27B1), as well as of the vitamin D receptor (VDR),
and the estrogen receptors (ER)-alpha and -beta (Table 1).BMC Cancer 2008, 8:13 http://www.biomedcentral.com/1471-2407/8/13
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Consistent with their origin from a well differentiated
tumour, Caco-2 cells exhibited the highest level of the dif-
ferentiation marker alkaline phosphatase. In contrast,
enzyme activity was low in COGA-1, and was barely
detectable in COGA-13 cells. Cellular differentiation
declined in the order Caco-2 > COGA-1A > COGA-13. The
proliferative potential varied inversely with differentia-
tion, as indicated by the rise in cyclin D1 and the drop in
p27 (Table 1).
All three cell clones were of epithelial origin according to
their expression of the epithelial cell marker CK8 (Table
1). Little vimentin was detected in Caco-2 and COGA-1A
cells, whereas in COGA-13, expression of vimentin
exceeded that of CK8. This indicates a high degree of epi-
thelial/mesenchymal transition in these least differenti-
ated cancer cells (Table 1).
The findings listed in Table 1 also indicate that all three
clones, notwithstanding marked differences in growth
characteristics and degree of differentiation, express the
VDR, and, as typical for colon epithelial cells, the ER-β
[24]. Consequently, all three clones can be expected to
respond to the receptor ligands, i.e., 1,25-(OH)2D3 and
17β-E2. Also, all three clones expressed the vitamin D
metabolising enzymes, 25-hydoxyvitamin D-24-hydroxy-
lase (CYP24) and 25-hydoxyvitamin D-1α-hydroxylase
(CYP27B1), though at markedly different levels. Of note,
CYP27B1 was abundant in Caco-2/AQ cells, as is typical
for rather differentiated colon carcinomas, whereas
CYP24 was overexpressed in COGA-13 cells consistent
with a low degree of differentiation [26].
IL-6 mRNA and protein expression in human colon 
carcinoma cells: effects of IL-1β, PGE2, 1,25-(OH)2D3, and 
17β-E2
RT-PCR analysis revealed a distinct, i.e., clone-specific,
pattern of basal and stimulated expression of IL-6 mRNA
in human colon carcinoma cells (Figure 1): As had been
observed previously, carcinoma cell clones derived from
well to moderately differentiated cancers, i.e. Caco-2 and
COGA-1A, expressed only small amounts of IL-6, as com-
pared with COGA-13 cells, which are derived from a
poorly differentiated tumour. In these cells, which had
already undergone substantial epithelial-mesenchymal
transition, IL-6 is conspicuously overexpressed.
In Caco-2/AQ cells, IL-6 gene activity and protein synthe-
sis were up-regulated only by IL-1β, whereas COGA-1A
responded only to 1,25-(OH)2D3. In COGA-13 cells, IL-6
levels were increased to some extent by PGE2, whereas IL-
1β increased IL-6 expression by three orders of magnitude
(Figure 1).
A more detailed picture of clonal sensitivity towards mod-
ulators of IL-6 was obtained when IL-1β, PGE2, 1,25-
(OH)2D3, and 17β-E2, singly or in appropriate combina-
tions, were added to colon carcinoma cell cultures (Table
Basal and stimulated expression of IL-6 mRNA and protein in  human colon carcinoma cell clones Figure 1
Basal and stimulated expression of IL-6 mRNA and protein in 
human colon carcinoma cell clones. Additions to the culture 
medium were: 10-6 M indomethacin, 10-7 M PGE2, 10-8 M 
1,25-(OH)2D3, 10-7 M 17β-E2, 5 ng/ml IL-1β. Upper part: 
Representative RT-PCR amplifications of mRNA transcripts 
specific for IL-6 (culture time 4 h). Expression of epithelial 
cell marker CK8 is shown for comparison. Lower part: IL-6 
release into medium during 24 h culture period. Data are 
means ± SD, n ≥ 4. Note that changes in IL-6 secretion by 
COGA-13 cells are given on a logarithmic scale. Statistically 
significant differences: *, P < 0.05; **, P < 0.01; ***, P < 0.001 
(Student's t-test).
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2). Overexpression of IL-6 by the COGA-13 clone became
apparent also at the protein level, as COGA-13 cells pro-
duced at least four times more IL-6 than Caco-2/AQ or
COGA-1A cells (Table 2). In none of the clones, IL-6 pro-
duction, regardless of whether basal or IL-1β-induced, was
changed when endogenous prostaglandin synthesis was
blocked by indomethacin (Table 2) or by the cyclooxyge-
nase (COX)-2 inhibitor, NS398 (not shown). As men-
tioned before, when 10-7 M PGE2 was added to COGA-13
cultures, a small increment in IL-6 release was observed.
17β-E2  was effective in COGA-13 cultures, where it
reduced basal IL-6 release by one third. However, the hor-
mone did not alter the extensive stimulation by IL-1β of
IL-6 synthesis (Table 2).
Sequence analysis of IL-6 promoter
We analysed the IL-6 gene promoter for the presence of
specific polymorphisms that are known to influence tran-
scriptional regulation of IL-6, e.g., by IL-1 and PGE2 [9]
(Table 3).
IL-6 effect on growth and differentiation of human colon 
carcinoma cell clones
To evaluate the mitogenic potency of IL-6 in Caco-2/AQ,
COGA-1A and COGA-13 cell cultures, graded concentra-
tions of the cytokine (0–100 ng/ml) were added to the
medium for 72 h. A dose dependent increase in cell divi-
sion was observed only in Caco-2/AQ cells, whereas the
growth rate in COGA-1A and GOGA-13 was unaltered
(Figure 2A). All three clones are endowed with the IL-6
receptor [5], but IL-6 proliferative signaling was trans-
duced to c-myc expression only in Caco-2 cells (Figure 2B):
IL-6 expression rose about fourfold after 24 h incubation
with 100 ng/ml rhIL-6 (Figure 2C).
In Caco-2 cell cultures, 10-8 M 1,25-(OH)2D3 abolished
the growth stimulatory effect of 10 ng/ml IL-6. Still a 50%
reduction was observed when cell division was stimulated
by IL-6 at the supraphysiological concentration of 100 ng/
ml (Figure 3). 1,25-(OH)2D3 completely prevented any
inhibitory effect of IL-6 on the activity of the differentia-
tion marker enzyme, alkaline phosphatase (Figure 4).
Discussion
The purpose of the present study was to evaluate the regu-
lation of IL-6 activity in human colon carcinoma cells by
classical modulators in respect to possible consequences
for tumour progression. In this regard, it is important to
note that each of the cell clones used in the present study,
i.e., Caco-2/AQ, COGA-1A, and COGA-13, according to
the characteristics shown in Table 1, represents a valid
model system for studies on differentiation-related
changes of human colon cancer cell functions during
tumour progression.
Overexpression of IL-6  seems to be a hallmark of
advanced tumour progression, since it has been observed,
apart from colon cancer [5], also in other human malig-
nancies, e. g., multiple myeloma, Kaposi's sarcoma [9], or
glioblastoma [27]. From data reported in Figure 1 it is
clear that human colon carcinoma cell clones derived
from well to moderately differentiated tumours, i.e. Caco-
2/AQ and COGA-1A, express relatively little IL-6, particu-
larly when compared to the rather undifferentiated clone
COGA-13. Not only IL-6 gene activity differs according to
the degree of differentiation, but also the extent of
unstimulated translation into protein is at least four times
higher in COGA-13 than in Caco-2 or COGA-1A (Table
2).
The promoter region of the IL-6 gene contains a number
of binding sites for transcription factors such as NFIL6 (C/
Table 2: Effect of modulators of IL-6 synthesis in human colon carcinoma cell clones
IL-6 secretion by human colon carcinoma cell clones
Addition Caco-2/AQ COGA-1A COGA-13
pg/ml fold change pg/ml fold change pg/ml fold change
None 4.86 ± 0.49 1.00 ± 0.10 5.49 ± 0.96 1.00 ± 0.17 21.20 ± 1.56 1.00 ± 0.07
indomethacin 0.88 ± 0.36 0.87 ± 0.25 1.02 ± 0.27
PGE2 1.03 ± 0.30 1.08 ± 0.11 1.79 ± 0.20***
1,25-(OH)2D3 1.13 ± 0.14 1.72 ± 0.17** 1.20 ± 0.03*
17β-E2 0.98 ± 0.08 1.26 ± 0.24 0.67 ± 0.12**
IL-1β 2.96 ± 0.26*** 0.85 ± 0.13 1035 ± 73***
IL-1β plus indomethacin 3.12 ± 0.28*** 0.93 ± 0.28 1147 ± 197***
IL-1β plus PGE2 2.83 ± 0.42*** 0.92 ± 0.29 1366 ± 210***
IL-1β plus 17β-E2 2.62 ± 0.24*** 0.79 ± 0.12* 1071 ± 33***
Additions to culture medium for 24 h were: indomethacin, 10-6 M; PGE2, 10-7 M; 1,25-(OH)2D3, 10-8 M; 17β-E2, 10-7 M; IL-1β, 5 ng/ml.BMC Cancer 2008, 8:13 http://www.biomedcentral.com/1471-2407/8/13
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EBPβ), NFκB, Fos/Jun (AP-1), CRBP, CREB etc. [9-12].
This explains the basic sensitivity of IL-6 towards classical
transcription modulating factors such as prostaglandins,
cytokines, steroid hormones etc. It is interesting to note
that PGE2 at 10-7 M had no effect on IL-6 expression and
protein synthesis in Caco-2 and COGA-1A cells, and
induced only a relatively small change in COGA-13 cells
(Table 2). Insensitivity of IL-6 to PGE2 can be deduced
also from the observation that in all three cell clones,
though they are endowed with cyclooxygenase-2 (COX-2)
activity [28], suppression of endogenous PG synthesis by
indomethacin or NS398 had no effect on basal and IL-1β-
stimulated IL-6 expression and protein secretion (Table
2). We conclude from this that in human colon cancer
cells, endogenous PG production, even when stimulated
Effect of 1,25-(OH)2D3 on rhIL-6-induced inhibition of differ- entiation of Caco-2/AQ cells Figure 4
Effect of 1,25-(OH)2D3 on rhIL-6-induced inhibition of differ-
entiation of Caco-2/AQ cells. Incubation time was 72 h. Con-
centrations in culture medium: 1,25-(OH)2D3, 10-8 M; rhIL-6, 
100 ng/ml. Cellular differentiation was evaluated from activity 
of the marker enzyme alkaline phosphatase. Data were calcu-
lated as mU/μg cellular protein and expressed as "percent of 
control" (means ± SD, n = 8). Statistically significant differ-
ences: *, P < 0.05; ***, P < 0.001 (Student's t-test).
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Table 3: Genotypes at three common polymorphic sites of the 
IL-6 promoter in human colon carcinoma cell clones
Cell clones Polymorphisms
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by IL-1β [28], is too low to affect IL-6 production, and
that, conversely, the chemopreventive effect on colon can-
cer development of COX-2 inhibitors [29] does not
involve changes of IL-6 expression.
Although all cell types investigated had been shown to
express ER-α and -β as well as the VDR (cf. Table 1), IL-6
expression in human colon carcinoma cells was only
modestly, if at all, influenced by the steroid hormones
17β-E2 and 1,25-(OH)2D3 (Figure 1; Table 2). 17β-E2 had
no effect on IL-6 synthesis in Caco-2/AQ and COGA-1A
cells, and inhibited IL-6 production by highly undifferen-
tiated COGA-13 cells only to an extent which makes effi-
cient suppression of IL-6 production in high grade cancers
by oestrogens very unlikely. This implies that prevention
of human colorectal cancer by oestrogens [30] does not
involve any direct effect on IL-6 expression.
Resistance to 1,25-(OH)2D3 in VDR-positive cells can be
due to rapid degradation of the steroid catalysed by the
25-(OH)-D-24-hydroxylase (cf. Table 1). This could
explain why 1,25-(OH)2D3 has no effect on IL-6 produc-
tion in COGA-13, or only a marginal one in COGA-1A
cells, but this is certainly not valid for Caco-2 cells, which
are generally responsive to VDR-mediated actions of 1,25-
(OH)2D3  [19]. The small 1,25-(OH)2D3-related incre-
ment of IL-6 production by COGA-1A cells seems to be
without relevance for the anti-mitogenic and pro-differen-
tiating effects of the hormone in human colon carcinoma
cells [19], since 1,25-(OH)2D3 effectively suppressed IL-6-
induced growth in differentiated Caco-2 cells (Figure 3).
At the same time, the pro-differentiating action of 1,25-
(OH)2D3 was completely preserved, even at extremely
high IL-6 concentrations (Figure 4).
The inefficiency of 17β-E2 and 1,25-(OH)2D3 in modulat-
ing  IL-6  transcriptional activity could result from
impaired or abrogated signal transduction downstream of
the ER-β or VDR, respectively, but may also be due to
clone-specific expression of IL-6 gene variants. This could
be the consequence of acquisition of mutations during
tumour development and progression, or, respectively,
caused by specific polymorphisms in the IL-6 promoter.
Terry  et al. [9] had identified four polymorphic sites,
which influence not only basal but also regulatable tran-
scription in a complex cooperative manner [12]. For
example, the -174C IL-6 haplotype is less efficiently trans-
lated into protein than its -174G counterpart, and conveys
resistance of IL-6 to the stimulatory action of IL-1 [12].
This may be the reason why Belluco et al. [31] found that
colon cancer patients carrying the -174G polymorphic IL-
6  gene had significantly higher IL-6 serum levels than
patients with the -174C genotype, particularly in the pres-
ence of hepatic metastases.
Our search for promoter polymorphisms (Table 3)
showed that all cell clones investigated express IL-6 vari-
ants which were identical only at -572 but different from
each other at sites -597 and -174. The -597A/-572G/-174C
haplotype, as solely present in COGA-13 cells, has been
identified by Terry et al. [9] as the one which, when trans-
fected in ECV304 cells, shows a comparable high tran-
scriptional activity (cf. also [12]). This may explain why
COGA-13 cells, particularly since they overexpress IL-6,
produce significantly more IL-6 than Caco-2 or COGA-1A
cells (Table 2). However, the same -597A/-572G/-174C
haplotype shows the least sensitivity to IL-1β [9]. There-
fore, the striking difference in the regulation of transcrip-
tional activity of IL-6 by IL-1β (cf. Table 2) could only be
due to cooperativity with still unknown promoter poly-
morphisms or, much more likely, due to mutational
changes in the IL-6  gene acquired during progression
through the adenoma/carcinoma sequence. These ques-
tions can only be answered when more information on
polymorphic sites and cancer-related mutations in the IL-
6 gene will be available.
From the results of the present study it is conceivable that
a highly critical situation for colon cancer patients may
arise, when COGA-13-type cells become abundant in a
cancerous lesion. If unopposed, massive release of IL-6
under the stimulation by IL-1β might accelerate tumour
progression to high stage malignancy by paracrine prolif-
erative action on IL-6-responsive, i.e., still differentiated
cells. At present, we are unaware of any means by which
IL-6 secretion from undifferentiated colon cancer cells can
be effectively suppressed. Alternatively, development of
anti-IL-6 or anti-IL-6 receptor monoclonal antibodies
could be beneficial for future adjuvant immune therapy
for cancer patients with genetic predisposition for IL-6
overexpression. In any case, screening for carriers of IL-6
gene variants with high susceptibility to transcriptional
dysregulation by IL-1β should be considered for identifi-
cation of individuals with high-risk for therapy-resistant
colorectal cancer.
Conclusion
Evidence is provided that in human colon cancer, undif-
ferentiated tumour cells are the main source of IL-6. The
cytokine can be released in massive amounts, particularly
when its expression is up-regulated by IL-1β. Transduction
of IL-6 signalling into up-regulation of c-myc expression
results in enhanced growth of colon carcinoma cells.
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